APR 09, 2020 4:36 PM PDT

Adjuvant immunotherapy proves effective for colon cancer

Results from a study published in Nature Medicine highlights the benefits of receiving pre-surgery immunotherapy for some types of colon cancer. The NICHE study was carried out by scientists at the Netherlands Cancer Institute and found that 100% of patients in a phase II clinical trial with MSI colon cancer benefited from immunotherapy pre-surgery, while 25% of MSS colon cancer patients saw benefits.

Pre-surgery immunotherapy, also known as neoadjuvant immunotherapy, is meant to keep cancer from metastasizing while also giving the immune system a head-start to recognize tumor variations. Ideally, this allows the immune system a better opportunity to respond once the tumor is removed by surgery.

While the researchers conducting the clinical trials hoped for positive results, they say they were blown away with their findings. 'A good response rate was on the cards in this group', says oncologist and project manager Myriam Chalabi. 'But a 100% rate is unprecedented. You don't dare hope it will be that good.'

Participating in the study were 40 patients with two different colon cancer subtypes: microsatellite-instable (MSI) tumors and microsatellite-stable (MSS) tumors. MSI means that the tumor is very susceptible to mutation; this subtype of colon cancer typically responds well to immunotherapy and the researchers showed that 100% of the patients responded well. MSS, on the other hand, does not typically respond well to immunotherapy; however, the researchers showed that 25% of the group responded well to adjuvant immunotherapy.

The researchers wanted to understand these unexpectedly positive results for MSS. “We looked at all the usual suspects, but they weren't the cause', says Chalabi. “We didn't see the same predictive factors as in melanoma, for instance. But in the end, we did find a new biomarker. If that proves to be predictive in follow-up studies, it could provide a simple way of identifying patients with MSS tumors who could benefit from immunotherapy.”

Photo: Pixabay

The researchers at the Netherlands Cancer Institute had previously shown in past studies that neoadjuvant immunotherapy has similar success outcomes for melanoma; they are simultaneously carrying out investigation on other types of tumors, as well. The researchers plan to continue monitoring the patients already involved in the colon cancer study for a minimum of three more years, in addition to increasing the number of patients involved. 'Only then can the new therapy be considered as a standard treatment', says Chalabi.

Sources: Nature Medicine, Eureka Alert

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
AUG 07, 2020
Plants & Animals
Do Tasmanian Devils Hold the Key to Tumor Inhibition?
AUG 07, 2020
Do Tasmanian Devils Hold the Key to Tumor Inhibition?
Thanks to a historic cartoon character, Tasmanian devils are commonly regarded as cantankerous and ferocious creatures. ...
AUG 14, 2020
Cancer
Controlling Tumor Blood Flow to Increase Therapy Effectiveness
AUG 14, 2020
Controlling Tumor Blood Flow to Increase Therapy Effectiveness
Nowadays, most cancer drugs target a protein or inhibit a critical cellular process. Modern therapies have varying level ...
AUG 19, 2020
Cancer
Testing the Toxicity of CDK Inhibitors and Radiotherapy
AUG 19, 2020
Testing the Toxicity of CDK Inhibitors and Radiotherapy
Drug targets often focus on one thing, inhibiting or activating some critical function in a cell. Cancer drugs are no di ...
AUG 16, 2020
Cancer
Cancer mapping shows health disparities in remote areas
AUG 16, 2020
Cancer mapping shows health disparities in remote areas
Scientists mapping cancer statistics have developed a new mathematical model to track health inequalities relating to th ...
OCT 01, 2020
Cancer
Understanding in vivo Metabolomics: C13 Isotope Studies
OCT 01, 2020
Understanding in vivo Metabolomics: C13 Isotope Studies
One key to understanding cancer metabolomics lies in the ability to accurately replicate the natural environment of the ...
OCT 06, 2020
Cannabis Sciences
Cannabis Use May Reduce Cancer Risk by 10%
OCT 06, 2020
Cannabis Use May Reduce Cancer Risk by 10%
A recent meta-analysis of 34 studies found that cannabis use may decrease one’s risk of developing certain kinds o ...
Loading Comments...